z-logo
open-access-imgOpen Access
Adrenal Suppression following Low-Dose Topical Clobetasol Propionate
Author(s) -
E. Magnus Ohman,
Susanne Rogers,
F. O. C. Meenan,
T. J. McKenna
Publication year - 1987
Publication title -
journal of the royal society of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.38
H-Index - 81
eISSN - 1758-1095
pISSN - 0141-0768
DOI - 10.1177/014107688708000709
Subject(s) - clobetasol propionate , medicine , metyrapone , adverse effect , dose , adrenal insufficiency , glucocorticoid , fluticasone propionate , dermatology , corticosteroid , endocrinology
The use of topical steroids is associated with adverse systemic effects such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis, and application of more than 50 g per week of clobetasol propionate cream has been shown to cause secondary adrenal failure. We describe 4 patients who used clobetasol propionate cream over a prolonged period; 3 patients used less than 50 g per week (7.5, 25 and 30 g per week) and yet all developed secondary adrenal failure for up to 4 months after cessation of therapy. Adrenal insufficiency following prolonged use of clobetasol propionate in moderate dosages may therefore be more common than previously recognized. It is suggested that the metyrapone test, which conveniently examines the entire HPA axis, should be employed in patients receiving long-term topical clobetasol propionate cream and that glucocorticoid supplementation should be given during episodes of stress, such as infections and surgery, for up to 4 months after cessation of therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom